BIORA THERAPEUTICS INC (BIOR)
US74319F3055 - Common Stock
Taking everything into account, BIOR scores 1 out of 10 in our fundamental rating. BIOR was compared to 587 industry peers in the Biotechnology industry. BIOR may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, BIOR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
BIOR had negative earnings in the past year.
In the past year BIOR has reported a negative cash flow from operations.
In the past 5 years BIOR always reported negative net income.
In the past 5 years BIOR always reported negative operating cash flow.
1.2 Ratios
BIOR has a Return On Assets of -397.61%. This is amonst the worse of the industry: BIOR underperforms 95.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -397.61% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-232.13%
ROA(5y)-209.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BIOR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BIOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
BIOR has more shares outstanding than it did 1 year ago.
BIOR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BIOR has been reduced compared to a year ago.
2.2 Solvency
BIOR has an Altman-Z score of -51.32. This is a bad value and indicates that BIOR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BIOR (-51.32) is worse than 93.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -51.32 |
ROIC/WACCN/A
WACC3.69%
2.3 Liquidity
BIOR has a Current Ratio of 0.30. This is a bad value and indicates that BIOR is not financially healthy enough and could expect problems in meeting its short term obligations.
BIOR has a worse Current ratio (0.30) than 96.41% of its industry peers.
A Quick Ratio of 0.30 indicates that BIOR may have some problems paying its short term obligations.
The Quick ratio of BIOR (0.30) is worse than 96.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.3 | ||
| Quick Ratio | 0.3 |
3. Growth
3.1 Past
BIOR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -73.63%.
BIOR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
The Revenue for BIOR have been decreasing by -87.44% on average. This is quite bad
EPS 1Y (TTM)-73.63%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q62.2%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-72.86%
Revenue growth 5Y-87.44%
Revenue growth Q2Q-100%
3.2 Future
BIOR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.61% yearly.
BIOR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 1438.27% yearly.
EPS Next Y74.58%
EPS Next 2Y32.36%
EPS Next 3Y18.61%
EPS Next 5YN/A
Revenue Next Year70017.6%
Revenue Next 2Y4024.53%
Revenue Next 3Y1438.27%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
BIOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BIOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BIOR's earnings are expected to grow with 18.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.36%
EPS Next 3Y18.61%
5. Dividend
5.1 Amount
BIOR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIORA THERAPEUTICS INC
NASDAQ:BIOR (5/16/2024, 7:00:02 PM)
After market: 0.74 +0 (+0.37%)0.7373
+0.02 (+3.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap26.45M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -397.61% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.3 | ||
| Quick Ratio | 0.3 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-73.63%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y74.58%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3Y-72.86%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y